NEW YORK, Aug. 3, 2021 /CNW/ -- MindMed (NASDAQ: MNMD)
(NEO: MMED) (DE: MMQ), a leading biotech company developing
psychedelic-inspired therapies, announced today that it will
participate in and financially support the Digital Medicine
Society's (DiMe) Digital Health Measurement Collaborative Community
(DATAcc), an effort to develop best practices and streamline the
medical field's approaches to measuring health using digital
technologies.
DATAcc comprises leaders from across the US government,
non-profit, and private sectors, including the US Food and Drug
Administration (FDA) , the US Department of Health and Human
Services, healthcare systems, medical technology companies, patient
advocates, biopharma, and policy organizations. The collaborative
will use interdisciplinary expertise, data, and cases to address
complex medical device challenges.
DATAcc members, including Dr. Dan
Karlin, Chief Medical Officer of MindMed, will meet for the
first time today, marking the launch of this collaborative community
dedicated to realizing the full potential of digital health
measurement as a powerful new tool to drive improvements in health
outcomes, health economics, and health equity. Activities will be
action-oriented, ranging from the development of best practices,
models, and frameworks to conducting pilots, and will be driven by
the diverse membership of DATAcc.
Ensuring access to effective and safe technologies requires a
multitude of perspectives and expertise to address, including those
of regulators. As stated in DiMe's press release dated May 25, 2021, "it is important to empower
stakeholders to ensure equitable access to high quality, safe, and
effective digital health technologies," says Anindita Saha, Assistant Director of the Digital
Health Center of Excellence in the Center for Devices and
Radiological Health, who will be the FDA liaison to DATAcc. "DATAcc
can advance efforts to build the science and evidence generation
for all people by keeping health outcomes and health equity front
and center."
Dr. Daniel Karlin, Chief Medical
Officer of MindMed, added, "We are eager to advance the science of
digital medicine through cooperation and collaboration.
Historically, medicine has relied on infrequent, subjective,
physician oriented measurements, which are largely carried out in
the clinical setting. This is especially true in psychiatry. The
reality is that illnesses, and the burdens they place on the
patient experience, have far more to do with how folks feel and
function when they're in their home environments and not in the
clinic. We see digital medicine and real world measurement as being
core to better understanding the conditions we are studying for
treatment with psychedelic-inspired medicines, and demonstrating
that our medicines are effective in helping treat individual
suffering while reducing the myriad costs of these illnesses
through enabling patient journeys toward recovery."
Together, on a continuing basis, the collaborative community
will explore six priority areas that include data governance, data
rights, digital inclusion, reimbursement, commercial models, and
the standardization of elements of digital sensing products and the
data they produce.
About MindMed
MindMed is a clinical-stage biotech
company that discovers, develops and deploys psychedelic inspired
medicines and therapies to address addiction and mental health. The
Company is assembling a compelling drug development pipeline of
innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ. For more
information: www.mindmed.co
MindMed Forward-Looking Statements
Certain statements
in this news release related to the Company constitute
"forward-looking information" within the meaning of applicable
securities laws and are prospective in nature. Forward-looking
information is not based on historical facts, but rather on current
expectations and projections about future events and are therefore
subject to risks and uncertainties which could cause actual results
to differ materially from the future results expressed or implied
by the forward-looking statements. These statements generally can
be identified by the use of forward-looking words such as "will",
"may", "should", "could", "intend", "estimate", "plan",
"anticipate", "expect", "believe", "potential" or "continue", or
the negative thereof or similar variations. Forward-looking
information in this news release include statements regarding
MindMed's involvement with DiMe and DATAcc, the ability to develop
digital technologies, participation of various members in DATAcc
and the success of creating digital technologies. Although the
Company believes that the expectations reflected in such
forward-looking information are reasonable, such information
involves risks and uncertainties, and undue reliance should not be
placed on such information, as unknown or unpredictable factors
could have material adverse effects on future results, performance
or achievements of the Company. There are numerous risks and
uncertainties that could cause actual results and the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information, including history of negative cash
flows; limited operating history; incurrence of future losses;
availability of additional capital; lack of product revenue;
compliance with laws and regulations; difficulty associated with
research and development; risks associated with clinical trials or
studies; heightened regulatory scrutiny; early stage product
development; clinical trial risks; regulatory approval processes;
novelty of the psychedelic inspired medicines industry; as well as
those risk factors discussed or referred to herein and the risks
described under the headings "Risk Factors" in the Company's
filings with the securities regulatory authorities in all of
the provinces and territories of Canada and available under the Company's
profile on SEDAR at www.sedar.com and with the U.S. Securities
and Exchange Commission on EDGAR at www.sec.gov. Should
one or more of these risks or uncertainties materialize, or should
assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technology-301346912.html
SOURCE MindMed